TCR αβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
Condition: Allogeneic Hematopoietic Cell Transplantation Intervention: Drug: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) Sponsor: Children's Hospital Medical Center, Cincinnati Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials